Pfizer Acquires Amplyx to Grow Anti-Infective Therapies Pipeline
Amplyx lead compound, Fosmanogepix which is a antifungal drug that is currently under development for the treatment of fungal infections
In May 3, 2021 Pfizer has announced thet they acquire Amplyx Pharmaceuticals to expands its anti-infectory pipeline. Amplyx lead compound, Fosmanogepix which is a antifungal drug that is currently under development for the treatment of fungal infections. This drug has the capability to target the fungal strain that is resistant for the standard care therapy.
“We are deeply committed to helping patients suffering from infectious diseases, continuously seeking opportunities to build our portfolio of anti-infective therapies,” Angela Lukin, global president of Pfizer Hospital, said in the announcement. “We’ve already invested in assets that, if approved, could help address drug-resistant bacterial infections and critical viral infections,” she continued. “With this acquisition, we look forward to progressing the development of a novel antifungal as well.”
Fosmanogepix is now in phase two clinical trial evaluating the safety and efficacy of the drug both intravenous and oral formulations for the treatment of patients with severe fungal infection which is life threatening caused by mold, yeasts and rare molds.Fosmanogepix passed its primary efficacy endpoint in a Phase 2 trial, with a success rate of 80 percent. There were no reported serious adverse events or discontinuations. The antifungal broad-spectrum activity in-vitro and has shown wide distribution to various tissues including the brain, lung, kidney, and eye. Due to the positive trial results, Fosmanogepix may allow for the transition from IV or oral, which would allow the treatment outside of the hospital setting.
